$1.07 Billion is the total value of RTW INVESTMENTS, LP's 47 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
BLCM | Exit | Bellicum Pharmaceuticals Inc | $0 | – | -157,489 | -100.0% | -0.06% | – |
NVUS | Exit | Novus Therapeutics Inc | $0 | – | -316,257 | -100.0% | -0.09% | – |
TPIV | Exit | Tapimmune Inc | $0 | – | -209,721 | -100.0% | -0.11% | – |
Exit | VIVUS INCnote 4.500% 5/0 | $0 | – | -4,000,000 | -100.0% | -0.19% | – | |
NVAX | Exit | Novavax Inc | $0 | – | -2,771,023 | -100.0% | -0.31% | – |
NVTRQ | Exit | Nuvectra Corp | $0 | – | -251,329 | -100.0% | -0.33% | – |
VKTX | Exit | Viking Therapeutics Inc | $0 | – | -500,000 | -100.0% | -0.52% | – |
PACB | Exit | PACIFIC BIOSCIENCES CALIF IN | $0 | – | -2,237,607 | -100.0% | -0.72% | – |
BVX | Exit | Bovie Medical Corp | $0 | – | -2,235,547 | -100.0% | -0.95% | – |
RMD | Exit | ResMed Inc | $0 | – | -147,400 | -100.0% | -1.02% | – |
QGEN | Exit | Qiagen NV | $0 | – | -775,324 | -100.0% | -1.76% | – |
ILMN | Exit | Illumina Inc | $0 | – | -82,621 | -100.0% | -1.82% | – |
CORI | Exit | CORIUM INTL INC | $0 | – | -3,610,632 | -100.0% | -2.06% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2019-02-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
ALNYLAM PHARMACEUTICALS INC | 36 | Q3 2023 | 19.7% |
MASIMO CORP | 32 | Q3 2023 | 5.8% |
LA JOLLA PHARMACEUTICAL CO | 31 | Q2 2022 | 9.7% |
REGENXBIO INC | 30 | Q4 2022 | 10.8% |
AGENUS INC | 29 | Q2 2022 | 9.0% |
PTC THERAPEUTICS INC | 28 | Q3 2023 | 12.8% |
DICERNA PHARMACEUTICALS INC | 28 | Q3 2021 | 10.8% |
MIRATI THERAPEUTICS INC | 26 | Q3 2023 | 6.2% |
ARGENX SE | 26 | Q3 2023 | 5.3% |
VERICEL CORP | 24 | Q3 2023 | 3.9% |
View RTW INVESTMENTS, LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
ROCKET PHARMACEUTICALS, INC. | September 19, 2023 | 18,188,457 | - |
ALLURION TECHNOLOGIES, INC. | August 11, 2023 | 3,457,707 | 7.4% |
Orchestra BioMed Holdings, Inc. | May 05, 2023 | 5,620,645 | 15.7% |
Renovacor, Inc.Sold out | April 05, 2023 | 0 | - |
Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Aptevo Therapeutics Inc.Sold out | February 14, 2023 | 0 | 0.0% |
ASLAN Pharmaceuticals LtdSold out | February 14, 2023 | 0 | 0.0% |
Athira Pharma, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
BELLUS Health Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Clearside Biomedical, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View RTW INVESTMENTS, LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13D/A | 2024-04-17 |
SC 13D/A | 2024-03-01 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View RTW INVESTMENTS, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.